Haemophilus influenzae: surface antigens and aspects of virulence
- PMID: 2193707
Haemophilus influenzae: surface antigens and aspects of virulence
Abstract
Haemophilus influenzae type b is a major cause of bacterial meningitis and other invasive diseases in children under four years of age. One surface antigen, the type b capsular polysaccharide, polyribosylribitol phosphate (PRP), is a primary virulence factor of the organism. Antibody directed against PRP is protective; however, the purified polysaccharide is poorly immunogenic in young children. Polysaccharide-protein conjugate vaccines have been prepared which are significantly more immunogenic and efficacious in young children compared to the plain polysaccharide vaccine. Noncapsular surface antigens may also play a role in the virulence of H. influenzae. Some mutants (or phase variants) which differ in lipooligosaccharide (LOS) structure exhibit decreased virulence in the infant rat model of bacteremia. Proteins including the IgA protease, pili, a 98K outer membrane protein (OMP) as well as OMPs P1, P2 and P6 have also been examined in considerable detail, but whether they have a role in the virulence of the organism remains to be determined. However, antibody directed against the 98K OMP as well as P1, P2 and P6 is protective in the infant rat model of bacteremia. The role of antibody directed against LOS epitopes in protection is less clear, due at least in part, to phase variation in LOS antigens. Characterization of one surface antigen of H. influenzae type b, the capsular polysaccharide, already has led to the prevention of many cases of Haemophilus disease. Characterization of the noncapsular antigens together with a more detailed understanding of the mechanisms of virulence, most likely will permit development of even better vaccines, and possibly better treatment modalities, in the future.
Similar articles
-
Immunogenicity of Haemophilus b conjugate vaccine (meningococcal protein conjugate) in children with prior invasive Haemophilus influenzae type b disease.Pediatr Infect Dis J. 1990 Sep;9(9):632-5. Pediatr Infect Dis J. 1990. PMID: 2235187
-
Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population.J Am Geriatr Soc. 2004 Nov;52(11):1883-7. doi: 10.1111/j.1532-5415.2004.52511.x. J Am Geriatr Soc. 2004. PMID: 15507066 Clinical Trial.
-
[Prospects for the vaccinal prevention of Haemophilus influenzae type b meningitis].Pathol Biol (Paris). 1983 Feb;31(2):144-8. Pathol Biol (Paris). 1983. PMID: 6341945 Clinical Trial. French.
-
[Immunological principles of polysaccharide-protein conjugate vaccination].Monatsschr Kinderheilkd. 1993 Oct;141(10):770-6; quiz 777, 812-3. Monatsschr Kinderheilkd. 1993. PMID: 7505396 Review. German.
-
[Haemophilus influenzae type B. Disease and prevention].Monatsschr Kinderheilkd. 1990 May;138(5):240-3. Monatsschr Kinderheilkd. 1990. PMID: 2198458 Review. German.
Cited by
-
Epitope-specific immune recognition of the nontypeable Haemophilus influenzae outer membrane protein 26.Hum Vaccin Immunother. 2013 Mar;9(3):625-35. doi: 10.4161/hv.23255. Epub 2013 Jan 4. Hum Vaccin Immunother. 2013. PMID: 23292125 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous